Premium
Biomimetic Glucose Trigger‐Insulin Release System Based on Hydrogel Loading Bidentate β‐Cyclodextrin
Author(s) -
Wang Renqi,
Tian Yuhui,
Wang Jiankang,
Song Wenxuan,
Cong Yong,
Wei Xuebing,
Mei Yingwu,
Miyatake Hideyuki,
Ito Yoshihiro,
Chen Yong Mei
Publication year - 2021
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.202104488
Subject(s) - insulin , medicine , self healing hydrogels , endocrinology , diabetes mellitus , fructose , in vivo , materials science , chemistry , biology , biochemistry , microbiology and biotechnology , polymer chemistry
Initiated by the specific binding between D‐glucose and biological receptors, the human body has a delicate metabolic system to regulate blood D‐glucose levels, but failing to release insulin would induce hyperglycemia or type I diabetes. While insulin delivery is an effective form of hyperglycemia therapy, the self‐regulated triggering of insulin release for on‐demand supplementation remains inadequate. Here, a biomimetic glucose trigger‐insulin release system, that is, a bidentate β‐cyclodextrin‐based hydrogel with preloaded insulin is presented; the dual self‐regulated system shows a specific D‐glucose response to realize accurate monitoring and simultaneous on‐demand trigger insulin release. The specific binding between D‐glucose and the bidentate β‐cyclodextrin induces the release of protons, causing macroscopic swelling of the hydrogel, subsequently triggering the on‐demand and long‐term supplementation of insulin. On the contrary, isomers of D‐glucose, such as D‐fructose and D‐galactose, cause shrinking of the hydrogel, and retard insulin release. In‐vivo studies in type I diabetic mice model ascertain that although the bidentate β‐CD hydrogel is preloaded with short‐activity insulin, it exerts long‐activity control of blood glucose level over 12 h.